FEB 22, 2018 6:00 AM PST

Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases

Presented at: Drug Discovery 2018
Speaker
  • Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint Luc
    Biography
      Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels, Belgium. He is the head of the department of Clinical Biochemistry of the Cliniques Universitaires Saint Luc. He is also member of the research unit on Endocrinology Diabetes and Nutrition of the Catholic University of Louvain. Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. Pr. D. Gruson is member of the division on Emerging Technology of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Pr. D. Gruson is also Fellow of the European Society of Cardiology.

    Abstract

    Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but also for risk stratification. Innovative biomarkers are studied to improve the sub-phenotyping of HF, to facilitate the diagnosis of HF with preserved ejection fraction, and to tailor therapeutic approaches. The soluble receptor of interleukin 33 (sST2) is one of these new biomarkers. In groups of patients at higher risk of HF (hypertension, diabetes), measurement of sST2 could identify patients requiring more sustained management. In the case of HF with reduced ejection fraction, sST2 would be a powerful marker for risk estimation but also to confirm treatment choice. In the case of HF with preserved ejection fraction, measurement of sST2 may be useful for confirming a diagnosis but also for the risk stratification of the patients and as companion marker for the treatment. Interestingly, the determination of the concentrations of sST2 is facilitated by the evolution of assays with new point of care testing methods. As for many innovative biomarkers, the transition of sS2T to routine testing requires strong multidiscilplinary exchanges with physicians.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 24, 2020 10:00 AM PDT
    C.E. CREDITS
    MAR 24, 2020 10:00 AM PDT
    DATE: March 24, 2020 TIME: 10:00 am PDT, 1:00pm EDT The Clampfit software module is a useful tool to manipulate and analyze electrophysiological data acquired by pCLAMP™ software. Rece...
    APR 16, 2020 9:00 AM PDT
    C.E. CREDITS
    APR 16, 2020 9:00 AM PDT
    DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
    Loading Comments...
    Show Resources